147 related articles for article (PubMed ID: 8847143)
1. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Rabbani SA; Harakidas P; Davidson DJ; Henkin J; Mazar AP
Int J Cancer; 1995 Dec; 63(6):840-5. PubMed ID: 8847143
[TBL] [Abstract][Full Text] [Related]
2. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
3. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Rabbani SA; Gladu J
Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
[TBL] [Abstract][Full Text] [Related]
4. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Achbarou A; Kaiser S; Tremblay G; Ste-Marie LG; Brodt P; Goltzman D; Rabbani SA
Cancer Res; 1994 May; 54(9):2372-7. PubMed ID: 8162583
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
6. Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Xing RH; Rabbani SA
Endocrinology; 1999 Sep; 140(9):4056-64. PubMed ID: 10465276
[TBL] [Abstract][Full Text] [Related]
7. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Evans DM; Sloan-Stakleff KD
Invasion Metastasis; 1998-1999; 18(5-6):252-60. PubMed ID: 10729770
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
[TBL] [Abstract][Full Text] [Related]
10. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
[TBL] [Abstract][Full Text] [Related]
11. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.
Rabbani SA; Harakidas P; Bowlin T; Attardo G
Cancer Res; 1998 Aug; 58(15):3461-5. PubMed ID: 9699681
[TBL] [Abstract][Full Text] [Related]
12. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo.
Rabbani SA; Harakidas P; Guo Y; Steinman D; Davidsen SK; Morgan DW
Int J Cancer; 2000 Jul; 87(2):276-82. PubMed ID: 10861487
[TBL] [Abstract][Full Text] [Related]
13. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
14. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice.
Billström A; Hartley-Asp B; Lecander I; Batra S; Astedt B
Int J Cancer; 1995 May; 61(4):542-7. PubMed ID: 7759160
[TBL] [Abstract][Full Text] [Related]
15. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3.
Liu DF; Rabbani SA
Prostate; 1995 Nov; 27(5):269-76. PubMed ID: 7479394
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Alonso DF; Tejera AM; Farias EF; Bal de Kier Joffe E; Gomez DE
Anticancer Res; 1998; 18(6A):4499-504. PubMed ID: 9891516
[TBL] [Abstract][Full Text] [Related]
17. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
18. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963
[TBL] [Abstract][Full Text] [Related]
19. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
20. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
